Ximluci (ranibizumab)
- Region
- 🇪🇺 EU
- Active substance
- ranibizumab
- Company
- STADA Arzneimittel AG
- Status
- Authorised
- Therapeutic area
- Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
- CHMP opinion
- Thu 15 Sep 2022
- EU approval
- Wed 09 Nov 2022
- Designations
- Biosimilar, Additional monitoring
- Application
- EMEA/H/C/005617
- ATC
- S01LA04
- Official record
- www.ema.europa.eu
Indication
Ximluci is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fovlussea Opinion · Accord Healthcare S.L.U.
- 🇪🇺 Lucentis Authorised · Novartis Europharm Limited
- 🇪🇺 Byooviz Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Epruvy (previously Ranibizumab Midas) Authorised · Midas Pharma GmbH
- 🇪🇺 Susvimo Authorised · Roche Registration GmbH
- 🇪🇺 Vislyfa Authorised · Lupin Europe GmbH
- 🇪🇺 Ranivisio Authorised · Midas Pharma GmbH
- 🇪🇺 Rimmyrah Authorised · Qilu Pharma Spain S.L.
- 🇺🇸 Nufymco Approved · Formycon Ag
- 🇺🇸 Ranluspec Approved · Lupin Limited
- 🇪🇺 Rexatilux Authorised · Intas Third Party Sales 2005 S.L.
- 🇪🇺 Ranluspec Authorised · Lupin Europe GmbH
Follow Ximluci
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.